Key Takeaways
- A class action lawsuit has been filed against Sana Biotechnology, Inc. for alleged violations of federal securities laws.
- The lawsuit covers all investors who purchased Sana securities between March 17, 2023, and November 4, 2024, with a deadline of May 20, 2025, to request Lead Plaintiff status.
- Recent disclosures indicated significant financial risks for the company, leading to stock price declines.
Details of the Lawsuit
Pomerantz LLP has initiated a class action lawsuit against Sana Biotechnology, Inc. and specific executives, claiming violations of federal securities laws. The suit was filed in the U.S. District Court for the Western District of Washington, featuring a class comprised of investors who acquired Sana securities from March 17, 2023, to November 4, 2024. Investors affected have until May 20, 2025, to apply to be the Lead Plaintiff.
Sana Biotechnology focuses on developing innovative therapies for various health conditions. Its product pipeline includes candidates like SC291 for B-cell malignancies, SC379 for CNS disorders, and SG299 for hematologic malignancies. Despite ongoing financial challenges associated with these developments, company executives assured investors of their ability to sustain operations and advance product candidates.
The complaint alleges that during the Class Period, Sana and its executives provided materially false information about the company’s finances and prospects. Specifically, the assertions claimed that:
1. Sana risked insufficient funding for ongoing projects.
2. The promise of product candidates SC291, SC379, and SG299 was overstated.
3. Planned reductions in funding and staffing could occur to prioritize more promising programs.
On October 10, 2023, Sana announced cuts to its fusogen platform, switching focus to its ex vivo cell therapy platform. This included halting the planned IND for SG299 and a 29% workforce reduction to better manage operating expenses while still aiming to keep cash burn below $200 million for 2024. This news led to an 8.95% drop in the stock price.
A subsequent press release on November 4, 2024, revealed the suspension of development for SC291 and SC379, reallocating resources to the type 1 diabetes program instead. This prompted a further 9.84% decline in stock value.
Pomerantz LLP, known for its expertise in corporate and securities class litigation, emphasizes its commitment to advocate for investors affected by corporate misconduct. The firm has historically obtained substantial recoveries on behalf of class members.
The content above is a summary. For more details, see the source article.